BIFRF (Biofrontera AG) Valuation Rank


BIFRF Biofrontera AG BIFRF
58 GF Score
Price $22.68
GF Value $31.34
! 4 Warning Signs
View Full Analysis

What is Biofrontera AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Biofrontera AG Valuation Rank Related Terms

BIFRF
58GF Score
Biofrontera AG BIFRF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Biofrontera AG (BIFRF) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera AG stock appears to be undervalued. The current stock price of $22.68 is trading 27.6% below its estimated GF Value™ of $31.34.

Key valuation signals for BIFRF:

  • Valuation Rank:
  • GF Value™: $31.34 vs. price of $22.68 (27.6% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the BIFRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera AG Business Description

Other Exchanges 0DOL:UKB8FK:Germany
Address Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED and BF-RhodoLED XL, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin. Geographically, the company generates maximum revenue from Germany, and the rest from Spain, the United Kingdom, the rest of Europe, and other regions.
58GF Score

Get the complete analysis for BIFRF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.68
Price
$31.34
GF Value